AstraZeneca's immunotherapy enters U.S. approval process

FRANKFURT (Reuters) - AstraZeneca's immunotherapy drug durvalumab, the British drugmaker's most important pipeline medicine, has been accepted for review by U.S. regulators against bladder cancer, potentially its first use.